Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Interventional × vorasidenib × Clear all
NCT06809322 2026-05-22

VIGOR

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Recruiting
468 enrolled
CNS

Astrocytoma

NCT05609994 2025-07-18

ViCToRy

Duke University

Phase 1 Recruiting
48 enrolled
CNS

Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡